Administration of cyclophosphamide during late pregnancy and early lactation: a case report.
Burkitt lymphoma was diagnosed in a patient during the third trimester of pregnancy. Treatment with a low-dose, seven-day course of intravenous cyclophosphamide gave a good response which permitted the pregnancy to be carried to term, with delivery of a normal infant. When the mother received cyclophosphamide during lactation while the baby was breast-fed, the infant's leukocyte and platelet counts were rapidly depressed. Results in this patient and a survey of reported cases in which cyclophosphamide was administered during pregnancy and lactation lead to the conclusions that (1) low-dose intravenous cyclophosphamide therapy is not hazardous to the fetus during late pregnancy; (2) mammary concentration of the drug is too toxic to the infant's bone marrow; and (3) breast-feeding the baby should be suspended during the period the mother is receiving cyclophosphamide treatment.
D000293:Adolescent; D001943:Breast Neoplasms / Q000188:drug therapy; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007774:Lactation / Q000187:drug effects*; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
D003520:Cyclophosphamide